As expected, the results showed that XRCC2 has a higher expression level in gliomas with higher malignancy and that the expression level of XRCC2 is lower in patients with IDH mutation and 1p/19q co-deletion than in the corresponding control group. The gene discussed is IDH1; the disease is glioma.